Snowflake Indefinite-Lived Research and Development Assets remained flat by 0.0% to $426.00K in Q3 2025 compared to the prior quarter. Year-over-year, this metric declined by 48.4%, from $826.00K to $426.00K. Over 4 years (FY 2021 to FY 2025), Indefinite-Lived Research and Development Assets shows an upward trend with a 18.0% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
An increase indicates aggressive investment in external innovation, while a decrease may signal project completion, commercialization, or impairment charges.
This represents the value of acquired in-process research and development (IPR&D) projects that have not yet reached com...
Common in pharmaceutical and medical device sectors where M&A is a primary driver of R&D pipelines.
indefinite_lived_rd_assets| Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 | Q3 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $826.00K | $826.00K | $826.00K | $826.00K | $826.00K | $826.00K | $826.00K | $826.00K | $826.00K | $826.00K | $826.00K | $826.00K | $826.00K | $826.00K | $826.00K | $826.00K | $826.00K | $426.00K | $426.00K |
| QoQ Change | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | -48.4% | +0.0% |
| YoY Change | — | — | — | — | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | +0.0% | -48.4% | -48.4% |